Hogan Lovells advised EyePoint Pharmaceuticals on the offering. Eyepoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a clinical-stage biopharmaceutical company, announced its US$161 million follow-on public offering of 14,636,363...
EyePoint Pharmaceuticals, Inc.’s US$161 Million Public Offering Of Common Stock
DRI Healthcare Trust’s Acquisition Of XENPOZYME From HLS Therapeutics Inc.
Hogan Lovells has advised HLS Therapeutics Inc. on the deal. HLS Therapeutics Inc. (TSX: HLS) sold its royalty interest and milestone payment obligations in the global...
Perspective Therapeutics’ $80 Million Shares Offering
Hogan Lovells advised Perspective Therapeutics on the deal. Perspective Therapeutics (NYSE AMERICAN: CATX) has completed an underwritten offering of 51,515,880 shares of its common stock at...
Optinose Inc’s $55 Million Common Stock Offering
Hogan Lovells guided Optinose, Inc. on the deal. Optinose, Inc. (NASDAQ:OPTN) has completed a registered direct offering of approximately US$55 million of its common stock and...
Perspective Therapeutics’ $69 Million Shares Offering and $20.8 Million Private Placement
Hogan Lovells advised Perspective Therapeutics on a series of strategic transactions. Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX) has completed a series of strategic transactions with Lantheus Holdings (NASDAQ:...
Novo Nordisk’s Research Collaborations with Omega Therapeutics and Cellarity
Goodwin advised Flagship Pioneering on the matter. Hogan Lovells acted for Omega Therapeutics, Inc. Novo Nordisk, Omega Therapeutics, Inc. (Nasdaq: OMGA) and Cellarity Inc. announced that Novo Nordisk...
EyePoint Pharmaceuticals, Inc.’s US$230 Million Public Offering Of Common Stock
Hogan Lovells advised EyePoint Pharmaceuticals on its offering. EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) closed its US$230 million follow-on public offering of 13,529,411 shares of common stock...
EyePoint Pharmaceuticals, Inc.’s US$115 Million Public Offering Of Common Stock
Hogan Lovells has advised EyePoint Pharmaceuticals, Inc. on the deal. Cowen and Guggenheim Securities acted as joint book-running managers for the offering. Among other uses, this...